Short Interest: It Seems Ampliphi Biosciences Corporation (NYSEMKT:APHB) Will Go Down. Just Reported More Shorted Shares

November 24, 2016 - By Marguerite Chambers   ·   0 Comments

Short Interest: It Seems Ampliphi Biosciences Corporation (NYSEMKT:APHB) Will Go Down. Just Reported More Shorted Shares

The stock of Ampliphi Biosciences Corporation (NYSEMKT:APHB) registered an increase of 33.51% in short interest. APHB’s total short interest was 721,200 shares in November as published by FINRA. Its up 33.51% from 540,200 shares, reported previously. With 135,600 shares average volume, it will take short sellers 5 days to cover their APHB’s short positions. The short interest to Ampliphi Biosciences Corporation’s float is 14.85%. The stock decreased 8.87% or $0.055 on November 23, hitting $0.569. About 765,196 shares traded hands or 306.23% up from the average. Ampliphi Biosciences Corp (NYSEMKT:APHB) has risen 6.00% since October 25, 2016 and is uptrending. It has outperformed by 0.59% the S&P500.

AmpliPhi Biosciences Corporation is a biotechnology company. The company has a market cap of $9.54 million. The Firm is focused on the discovery, development and commercialization of phage therapeutics. It currently has negative earnings. The Firm is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products.

APHB Company Profile

AmpliPhi Biosciences Corporation, incorporated on March 9, 1989, is a biotechnology company. The Firm is focused on the discovery, development and commercialization of phage therapeutics. The Firm is engaged in identifying, characterizing and developing naturally occurring bacteriophages with its collaboration partners in bacteriophage biology, synthetic biology and manufacturing, to develop second-generation bacteriophage products. The Firm is engaged in developing these phage product candidates using a discovery and development platform, which is designed for identification, characterization and manufacturing of multiple phage therapies. Each product candidate combines several chosen phages, which target a specific disease-causing bacterial pathogen, such as staphylococcus aureus (S. aureus), Pseudomonas aeruginosa (P. aeruginosa) and clostridium difficile (C. difficile).

More recent Ampliphi Biosciences Corp (NYSEMKT:APHB) news were published by: Quotes.Wsj.com which released: “News Ampliphi Biosciences Corp.APHB” on June 24, 2011. Also Seekingalpha.com published the news titled: “AmpliPhi Biosciences Sweetens Follow-On Offering Terms” on November 13, 2016. Businesswire.com‘s news article titled: “AmpliPhi Biosciences Presents Data Showing Bacteriophage Product Candidate …” with publication date: April 12, 2016 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Marguerite Chambers


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>